United States Biotechnology & Medical Research

Array BioPharma Inc (ARRY)

Track

Stock chart
Ticker: ARRY Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Sandor Victor
Chief Medical Officer
1 sale — total 2,851,000 USD
Planned sale 4 Jun 2019
Value US$3,066,714.09 | Price 324.03 | Shares 12,622
Planned sale 3 Jun 2019
Value US$1,037,954.33 | Price 422.15 | Shares 63,705
Planned sale 30 May 2019
Value US$432,520.00 | Price 27.50 | Shares 15,728
Planned sale 28 May 2019
Value US$2,022,929.74 | Price 27.00 | Shares 74,915
Planned sale 23 May 2019
Value US$1,076,845.70 | Price 26.50 | Shares 40,634
Planned sale 21 May 2019
Value US$333,900.00 | Price 26.50 | Shares 12,600
Buy 19 Feb 2019
Value US$115,998.00 | Price 23.20 | Shares 5,000
Planned sale 7 Feb 2019
Value US$1,874,301.00 | Price 22.05 | Shares 85,000
Planned sale 7 Feb 2019
Value US$2,380,015.00 | Price 21.64 | Shares 110,000
Planned sale 7 Feb 2019
Value US$4,041,756.36 | Price 21.58 | Shares 187,264
Planned sale 6 Feb 2019
Value US$234,240.00 | Price 20.00 | Shares 11,712
Sale 6 Feb 2019
Value US$104,261.00 | Price 20.85 | Shares 5,000
Sale 6 Feb 2019
Value US$104,120.50 | Price 20.82 | Shares 5,000
Sale 6 Feb 2019
Value US$512,692.50 | Price 20.51 | Shares 25,000
Sale 6 Feb 2019
Value US$4,798,510.65 | Price 20.03 | Shares 239,626
Planned sale 5 Feb 2019
Value US$800,000.00 | Price 20.00 | Shares 40,000
Planned sale 31 Jan 2019
Value US$2,101,541.04 | Price 18.53 | Shares 113,438
Planned sale 30 Jan 2019
Value US$1,825,370.00 | Price 18.25 | Shares 100,000
Planned sale 25 Jan 2019
Value US$252,523.40 | Price 18.00 | Shares 14,029
Planned sale 18 Jan 2019
Value US$22,518.00 | Price 18.00 | Shares 1,251
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2019-06-06 2019-06-04 PlS Planned sale
0.8
Sandor Victor

Chief Medical Officer
12,622 -42.9%
324.03
US$3,066,714 		12,622 -42.9% 324.03 US$3,066,714
2019-06-03 2019-06-03 PlS Planned sale
0.8
Sandor Victor

Chief Medical Officer
63,705 +35.9%
422.15
US$1,037,954 		63,705 +35.9% 422.15 US$1,037,954
2019-06-03 2019-05-30 PlS Planned sale
0.8
Sandor Victor

Chief Medical Officer
98,693 +30.3%
161.00
US$447,291 		98,693 +30.3% 161.00 US$447,291
2019-05-28 2019-05-28 PlS Planned sale
0.8
Sandor Victor

Chief Medical Officer
74,915 -26.3%
27.00
US$2,022,930 		74,915 -26.3% 27.00 US$2,022,930
2019-05-28 2019-05-23 PlS Planned sale
0.8
Sandor Victor

Chief Medical Officer
40,634 -14.6%
26.50
US$1,076,846 		40,634 -14.6% 26.50 US$1,076,846
2019-05-23 2019-05-21 PlS Planned sale
0.8
Sandor Victor

Chief Medical Officer
12,600 -5.0%
26.50
US$333,900 		12,600 -5.0% 26.50 US$333,900
2019-02-21 2019-02-19 B Purchase
2.7
COX CARRIE SMITH
5,000 +166.7%
23.20
US$115,998 		5,000 +166.7% 23.20 US$115,998
2019-02-08 2019-02-07 PlS Planned sale
Haddock Jason

CFO
85,000 -73.9%
22.05
US$1,874,301 		85,000 -73.9% 22.05 US$1,874,301
2019-02-08 2019-02-07 PlS Planned sale
0.8
Squarer Ron

CEO
110,000 -31.5%
21.64
US$2,380,015 		110,000 -31.5% 21.64 US$2,380,015
2019-02-08 2019-02-07 PlS Planned sale
3.6
Saccomano Nicholas A

CSO
187,264 -56.8%
21.58
US$4,041,756 		187,264 -56.8% 21.58 US$4,041,756
2019-02-08 2019-02-06 PlS Planned sale
Haddock Jason

CFO
11,712 -28.0%
20.00
US$234,240 		11,712 -28.0% 20.00 US$234,240
2019-02-08 2019-02-06 S Sale
LEFKOFF KYLE
5,000 -20.0%
20.85
US$104,261 		5,000 -20.0% 20.85 US$104,261
2019-02-08 2019-02-06 S Sale
LEFKOFF KYLE
5,000 -16.7%
20.82
US$104,120 		5,000 -16.7% 20.82 US$104,120
2019-02-08 2019-02-06 S Sale
LEFKOFF KYLE
25,000 -52.4%
20.51
US$512,692 		25,000 -52.4% 20.51 US$512,692
2019-02-08 2019-02-06 S Sale
Robbins Andrew R

COO
239,626 -80.0%
20.03
US$4,798,511 		239,626 -80.0% 20.03 US$4,798,511
2019-02-07 2019-02-05 PlS Planned sale
2.5
Oltmans Curtis Gale

General Counsel
40,000 -72.7%
20.00
US$800,000 		40,000 -72.7% 20.00 US$800,000
2019-02-01 2019-01-31 PlS Planned sale
0.8
Squarer Ron

CEO
113,438 -32.2%
18.53
US$2,101,541 		113,438 -32.2% 18.53 US$2,101,541
2019-02-01 2019-01-30 PlS Planned sale
0.8
Squarer Ron

CEO
100,000 -29.5%
18.25
US$1,825,370 		100,000 -29.5% 18.25 US$1,825,370
2019-01-29 2019-01-25 PlS Planned sale
2.5
Oltmans Curtis Gale

General Counsel
14,029 -78.2%
18.00
US$252,523 		14,029 -78.2% 18.00 US$252,523
2019-01-23 2019-01-18 PlS Planned sale
2.5
Oltmans Curtis Gale

General Counsel
1,251 -24.2%
18.00
US$22,518 		1,251 -24.2% 18.00 US$22,518
Explore more

More insider trading research around Array BioPharma Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America